

AbolerIS Pharma signed with Ouest Valorisation an exclusive world-wide license to develop new first-in-class anti-CD45RC monoclonal antibodies.

- Anti-CD45RC monoclonal antibodies have a unique mechanism of action and are potent immune-modulators ;
- Anti-CD45RC monoclonal antibodies can be applied as immunotherapy for organ and bone marrow transplantation as well for autoimmunity.

NANTES, France, December 1st, 2020,

AbolerIS Pharma, a biotechnology company developing innovative immunotherapies, announces that the company has entered into an agreement with SATT Ouest Valorisation, on behalf of INSERM, CNRS (public French research organizations), Nantes University Hospital and Nantes University, to license a first-in-class anti-CD45RC monoclonal antibodies.

These new antibodies target pathogenic T cells involved in tissue-destructive immune responses in acute graft-vs.-host disease, rejection of transplanted organs, autoimmune diseases and immune-mediated inflammatory diseases. This treatment aims to promote immune tolerance and thus decrease or eliminate life-long immunosuppressive treatments.

Under the terms of the agreement, AbolerIS Pharma is granted an exclusive worldwide license for a family of four patents filed by the Center of Research in Transplantation and Immunology (CRTI). This license includes a worldwide and exclusive option for AbolerIS Pharma to further develop any products and applications derived from this antibody.

This license will focus on the development of an antibody that targets CD45RC (program ABIS-45RC) inducing the apoptosis of naïve cells poised to develop Th1 proinflammatory cells as well as terminally differentiated T cells. This allows the development of antigen-specific regulatory T cells.

« Licensing such leading-edge innovations on strategic therapeutic areas is definitively at the core of our Tech Transfer Office missions, moving early research results forward to a stage where a biotech startup catch it. Beyond science, it's also a human adventure with the research team embedded in the startup project, as co-founders », said Vincent Lamande, CEO of Ouest Valorisation.

This new target was discovered by team 2 of CRTI co-led by Dr. Ignacio Anegon, M.D. (DR1 INSERM) and Dr. Carole Guillonéau PhD (DR2 CNRS). Both researchers are co-founders of AbolerIS Pharma. The team demonstrated the efficacy of this antibody in several pre-clinical models including cardiac transplantation, Duchene's dystrophy, human skin transplantation and graft-versus-host disease in mice humanized for their immune system.

" The license of the patents to AbolerIS Pharma will bring funding and expertise to move anti-CD45RC antibodies and derivatives from preclinical models to the clinic in the most efficient manner and in the shortest delays", Dr. Anegon commented.

" The CD45RC target is unique in its expression pattern and anti-CD45RC antibodies have a mechanism of action allowing not only elimination of pathogenic cells, but also protection by regulatory cells. This license will establish AbolerIS positioning on innovative immunotherapies

for the treatment of autoimmune diseases and transplant rejection” Dr. Guillonnet commented.

“ We are very pleased to support this breakthrough science in translating it into medicines which can make the clinical difference for patients” said Dr. Ann Meulemans, CEO of AbolerIS Pharma.

About AbolerIS Pharma (<http://aboleris-pharma.com/>)

AbolerIS Pharma is a recently created biotechnology company that develops new immunotherapies in the fields of autoimmune diseases, immune-mediated inflammatory diseases and transplantation. The company develops several molecules, such as the anti-CD45RC monoclonal antibody, a cytokine and other molecules are in its pipeline. Together with the optimization of its molecules, research and development are key sectors of AbolerIS Pharma activity. AbolerIS Pharma recently obtained seed investment for 2.5 M€ from Newton Biocapital and Turenne Santé/Sham Innovation Santé (<http://aboleris-pharma.com/wp-content/uploads/2020/11/press-release-seed-AbolerIS-Pharma-Vf.pdf>)

About SATT Ouest Valorisation

BRINGING FORWARD LABORATORY INNOVATIONS AND CONVERTING THEM INTO INNOVATIVE PRODUCTS

“DeepTech” by nature, Ouest Valorisation is a SATT, Société d’Accélération du Transfert de Technologies or Technology Transfer Acceleration Company – namely a Technology Transfer Office. Our mission is to add value to the results produced by public research laboratories, in Brittany and the Pays de la Loire, and to offer socio-economic actors attractive innovation resources. We give access at existing companies or startups to deeptech innovation.

Investing in research laboratories at the early stage and securing intellectual property (IP) rights for these promising technologies, we lead and negotiate the legal and contractual licensing and collaboration agreements, playing a full role in value creation and social impact.

Contact :

Bruno WESTEEL // Director, Marketing & Communication
+33 6 18 70 31 91 // bruno.westeel@ouest-valorisation.fr

About CRTI <http://www.itun.nantes.inserm.fr/>

The CRTI is a joint research unit (UMR 1064) created by INSERM and Université de Nantes. The CRTI is located at the Nantes University Hospital where it constitutes with several clinical departments the Institute of Transplantation Urology and Nephrology. The CRTI is part of the Labex Immunology Graft Oncology, a regional cluster of immunology laboratories and of the Nantes cluster of research (SFR). This unique environment fosters interactions between basic scientists and clinicians, supported by the most updated technological platforms and explains the strong commitment of the CRTI to translational research. The main and long-term objectives of CRTI are to improve treatments and patient monitoring in transplantation and immune-mediated inflammatory diseases through understanding immune responses, developing new immunotherapeutics, biomarkers and tools for personalized medicine and developing alternative strategies for organ or tissue replacement.

For further information please contact :

Ann Meulemans (PhD), CEO AbolerIS Pharma
e-mail : ann.meulemans@aboleris-pharma.com